BACKGROUND Non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH), appears to be increasingly common worldwide. Its histopathology and the effects of nutrition on liver function have not been fully determined. AIM To elucidate the cellular mechanisms of NAFLD induced by a methionine-choline-deficient (MCD) diet in mice. Particular focus was placed on the rol...

1Division of Gastroenterology, Ospedale di Acireale, Azienda Sanitaria Provinciale di Catania, Catania, Italy 2Liver Unit, Department of Gastroenterology, Tel-Aviv Medical Center, Tel-Aviv, Israel 3School of Public Health, University of Haifa, Haifa, Israel 4Department of Biomedical Sciences and Biotechnologies, University of Catania, Catania, Italy 5Center for Human Nutrition and Atkins Center...

Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes diseases: 25% population European countries have signs NAFLD, 10–20% patients with steatosis develop an inflammatory process (non-alcoholic steatohepatitis), which, if not treated, can transform into fibrosis and cirrhosis. In people, NAFLD diagnosed, prognosis inaccurate, there are no licensed methods treating disease. ...

UNLABELLED The present review includes translational and clinical research that characterize non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Clinical and experimental evidence led to the recognition of the key toxic role played by lipotoxicity in the pathogenesis of NAFLD. The current understanding of lipotoxicity suggests that organ injury is initiated by th...

BACKGROUND AND AIM Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide, with a prevalence of 20%-40% in Western populations. The purpose of this article is to review data related to lifestyle changes in patients with NAFLD. METHOD We searched a public domain database (PubMed) with the following categories: disease (NAFLD, fatty liver, and non-alcoholi...

Non-alcoholic fatty liver had been believed to be a non-progressive benign disease. However, Ludwig et al. described some patients who exhibited progressive steatohepatitis without habitual alcohol drinking (Ludwig et al., 1980) and referred to this disease as non-alcoholic steatohepatitis (NASH). Later, NASH and non-progressive simple steatosis patients were included in the single disease enti...

Conophylline (CnP), a vinca alkaloid extracted from the leaves of the tropical plant Ervatamia microphylla, attenuates hepatic fibrosis in mice. However, little is known about whether CnP inhibits steatosis, inflammation, and fibrosis in non-alcoholic steatohepatitis (NASH) in mice. A methionine-choline-deficient (MCD) diet was administered to male db/db mice as a NASH model, and CnP (1 μg/kg/d...